17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma

NCT00117988 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

22

Enrollment

NIH

Sponsor class

Conditions

Anaplastic Large Cell Lymphoma
Recurrent Adult Hodgkin Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions

DRUG: tanespimycin

Sponsor

National Cancer Institute (NCI)